FRANKFURT, Germany–(WIRE GANACSI)–Merz Therapeutics, oo ah hogaamiyaha dhanka neurotoxins-ka iyo ganacsiga hoos yimaada Merz Group, iyo Teijin Pharma Limited, oo ah shirkada xudunta u ah ganacsiga daryeelka caafimaadka ee Teijin Group, ayaa si wada jir ah maanta ugu dhawaaqay in Teijin Pharmaceuticals ay ku guulaysatay Oggolaanshaha Wasaaradda Caafimaadka, Shaqada iyo Daryeelka ee Japan (MHLW) si ay u isticmaasho Xeomin® (incobotulinumtoxinA) 50, 100 ama 200 unug ee cirbadeynta muruqa ee daawaynta xuubabka hoose.
Xubinta lugaha hoose waa calaamad muujinaysa xanuunka sare ee neuron syndrome, kaas oo inta badan lagu muujiyo kor u kaca murqaha addimada iyo xiisaha xad dhaafka ah ee falcelinta fidsanaanta sida daba-galka istaroogga.Calaamadaha ugu waaweyn waa dhib u socodka si caadi ah iyo khatarta sii kordheysa ee dhicis sababtoo ah jirridda aan degganeyn, qallafsan ama dhaqdhaqaaqa nolol maalmeedka.Daawaynta caadiga ah ee bararka lugaha waxaa ka mid ah baxnaanin jireed iyo isticmaalka nasashada murqaha afka ama xannibayaasha neuromuscular, sida botulinum toxin nooca A.
Stefan Brinkmann, oo ah maamulaha guud ee Merz Therapeutics, ayaa yiri: "Oggolaanshaha la dheereeyey waxay calaamad u tahay guul muhiim ah oo ku saabsan Merz Therapeutics waana natiijada iskaashiga dhow ee aan la leenahay Teijin Pharmaceuticals.Waxaan rajeyneynaa in la-hawlgalayaasheena ay si guul leh u soo bandhigi doonaan tilmaantan muhiimka ah ee caafimadka ee dhakhaatiirta Japan iyo bukaannada."
Dr. Stefan Albrecht, Madaxweyne ku xigeenka Sare ee Global R&D, Merz Therapeutics: “Balaadhinta summadan Japan waa tusaale kale oo muuqda oo faa'iidooyinka ay Xeomin ® siiso bukaanno badan oo qaba istaroog ka dib.Dhakhaatiirtu hadda waxay dooran karaan inay daaweeyaan bararka hoose iyo sare ee cirifka, ama waxay noqon karaan kuwo dabacsan markii loo baahdo Si taxadar leh u codso qiyaasaha gaarka ah.Waan ku hanweynahay guushan, gaar ahaan wada-shaqeynta wanaagsan ee aan la leenahay lammaaneheenna Teijin."
Madaxweynaha Teijin Pharmaceutical Ichiro Watanabe ayaa yiri: "Teijin Pharmaceutical waxay bixisaa daawooyin kala duwan, oo ay ku jiraan daawaynta lafaha iyo qalabyada caafimaadka, sida mowjadda dhawaaqa waxay kordhisay nidaamka bogsashada jabka ee bukaanka qaba cudurrada muruqyada.Annaga oo ka jawaabayna isbeddellada tirakoobka iyo wacyigelinta caafimaadka oo kordhay, Waxaan bilaabaynaa dawooyin iyo xalal cusub oo wax ku ool ah, oo ay ku jiraan xaqiijinta bulsho waara.Teijin Pharmaceuticals waxay sii wadaa inay gacan ka geysato hagaajinta tayada nolosha (QOL) ee bukaannada iyadoo siinaya doorashooyin cusub oo daaweyn ah oo loogu talagalay cudurrada leh baahiyaha aan la daboolin.”
Xeomin® waxay si wax ku ool ah u daaweysaa dareemaha dareemaha ee cholinergic-ka iyada oo daciifinaysa murqaha iskaa wax u qabso ah, waxayna yaraynaysaa murqaha iyada oo joojinaysa sii deynta neurotransmitter ee loo yaqaan acetylcholine.Neurotoxin-ka aadka loo sifeeyay ayaa ah walaxda kaliya ee firfircoon ee Xeomin®.Waxa lagu sameeyaa iyada oo ka saarta borotiinnada isku dhafan nooca A botulinum toxin ee ay soo saarto Clostridium botulinum iyada oo la adeegsanayo tignoolajiyada sifaynta ee ay sameeyeen Merz Pharma GmbH & Co. KGaA.La'aanta borotiinno isku dhafan ayaa u oggolaanaya Xeomin® inay yareyso soo saarista unugyada difaaca jirka oo yareyn kara waxtarka.Horumar la taaban karo oo ku yimid buundada flexor plantar flexor modified ashworth scale (MAS) ayaa lagu arkay tijaabada caafimaad ee wajiga III ee Japan.
Xeomin® waxaa qaybiya Merz Pharmaceuticals GmbH in ka badan 70 wadan waxaana loo isticmaalaa in lagu daweeyo bukaanada qaba calaacalaha sare, dystonia ilmo-galeenka, blepharospasm ama candhuuf xad dhaaf ah.Teijin Pharmaceuticals ayaa la saxeexday shati gaar ah iyo heshiis horumarinta wadajirka ah ee Xeomin® ee Japan oo ay la gashay Merz 2017, waxayna bilowday iibinta gaarka ah ee Xeomin® bishii Diseembar 2020 ka dib markii ay oggolaansho ka heshay Wasaaradda Caafimaadka, Shaqada iyo Daryeelka (MHLW) ee Japan.Iyada oo ku saleysan tijaabada bukaan-socodka ee Marz's Wajiga III ee Japan, oggolaanshaha cusub ee dhowaan la helay ayaa beddelay qaar ka mid ah oggolaanshaha la oggolaaday.
Guud ahaan, dadka waaweyn, Xeomin® waa in lagu duraa muruqyo adag oo badan.* Qiyaasta ugu badan ee maamul kasta waa 400 unug, laakiin waa in si habboon loo dhimo qiyaasta ugu yar iyadoo loo eegayo nooca iyo tirada muruqyada tonic ee bartilmaameedka ah.Haddii saamaynta qiyaasta hore ay yaraato, qiyaasaha soo noqnoqda waa la oggol yahay.Inta u dhaxaysa qaadashada daawada waa inay ahaataa 12 toddobaad ama ka badan, laakiin waxa laga yaabaa in la soo gaabiyo 10 toddobaad iyadoo ku xidhan calaamadaha.
* Myotonic: gastrocnemius (madaxa dhexdhexaadka ah, madaxa lateral), soleus, tibialis dambe, flexor digitorum longus, iwm.
Merz Therapeutics waa ganacsi Merz Pharmaceuticals GmbH u heellan horumarinta nolosha bukaannada adduunka oo dhan.Cilmi baaristeeda aan kala go'a lahayn, horumarinta iyo dhaqanka hal-abuurka, Merz Therapeutics waxay ku dadaalaysaa inay buuxiso baahiyaha bukaanka ee aan la daboolin oo ay gaarto natiijooyin wanaagsan.Merz Therapeutics waxay doonaysaa inay buuxiso baahiyaha gaarka ah ee dadka la ildaran cilladaha dhaqdhaqaaqa, cudurrada neerfaha, cudurrada beerka, iyo xaaladaha kale ee caafimaad ee si dhab ah u saameeya tayada nolosha bukaanka.Merz Therapeutics waxay xarunteedu tahay Frankfurt, Germany, oo xafiisyo wakiil ah ku leh in ka badan 90 waddan, iyo laan Waqooyiga Ameerika ku taal Raleigh, North Carolina.Merz Pharmaceuticals GmbH waa qayb ka mid ah Merz Group, shirkad gaar loo leeyahay oo qoysku leeyihiin taas oo ay ka go'an tahay inay horumariso hal-abuurnimo daboolaysa baahida bukaannada iyo macaamiisha in ka badan 110 sano.
Teijin (Tokyo Stock Exchange code: 3401) waa koox caalami ah oo tignoolajiyada hogaaminaysa oo bixisa xalal horumarsan oo ku saabsan qiimaha deegaanka;badbaadada, amniga, iyo dhimista masiibooyinka;iyo sidoo kale isbeddelka tirada dadka iyo kor u kaca wacyiga caafimaadka.Teijin asal ahaan waxaa la aasaasay 1918 oo ah soo saaraha ugu horreeya ee rayn ee Japan, waxaana uu hadda u horumaray shirkad gaar ah oo ka kooban saddex goobood oo ganacsi oo muhiim ah: qalabyada waxqabadka sare leh oo ay ku jiraan aramid, fiber carbon iyo walxaha isku dhafan, iyo sidoo kale resin iyo processing caag ah, Film. , fiber polyester iyo farsamaynta alaabta;daryeelka caafimaadka, oo ay ku jiraan dawooyinka iyo qalabka caafimaadka guriga ee lafaha/lafyada, hab-dhiska neefsiga, iyo cudurrada wadnaha iyo xididdada dheef-shiid kiimikaadka, kalkaalinta iyo daryeelka calaamadaha hore;iyo IT, oo ay ku jiraan daaweynta, shirkadaha iyo xalalka B2B ee nidaamyada dadweynaha, iyo sidoo kale software baakadaysan iyo adeegyada internetka ee B2C ee madadaalada dhijitaalka ah.Sida lagu muujiyay bayaanka calaamadda "Chemistry Human, Solutions Human", Teijin waxay si qoto dheer uga go'an tahay daneeyayaasha waxayna ujeedadeedu tahay inay noqoto shirkad taageerta bulshada mustaqbalka.Kooxdu waxay ka kooban tahay in ka badan 170 shirkadood waxayna leeyihiin ku dhawaad 20,000 oo shaqaale ah 20 waddan/gobollada adduunka ah.Sannad xisaabeedka dhammaanaya Maarso 31, 2021, Teijin wuxuu ku dhawaaqay iibka la isku daray ee 836.5 bilyan yen ($7.7 bilyan) iyo guud ahaan hantida 1.036.4 bilyan yen ($9.5 bilyan).
Waqtiga post: Seb-10-2021